Approval based on a separate phase III trial among Chinese patients reinforcing mepolizumab’s efficacy and safety data
Acquisition includes HPN328, an investigational delta-like ligand 3 (DLL3) targeting T-cell engager being evaluated in certain patients with small cell lung cancer and neuroendocrine tumors
Base4's drug discovery platform allows its collaborators to evaluate billions of novel small molecules to identify and progress RNA-modulators for important diseases
The company has received five final approvals
Roche will pay a purchase price of USD 295 million and an additional payment of up to USD 55 million
Innovent will supply sintilimab for the collaborated clinical trial
Elpiscience will receive up to US $37 million, including the upfront payment and license option fees
The product is expected to be launched in December 2023
The transfer of the distribution rights will strengthen Sandoz's immunology and biosimilar portfolio
V116 is an investigational, 21-valent pneumococcal conjugate vaccine specifically designed to protect adults
Subscribe To Our Newsletter & Stay Updated
